Review Article
Adipose Tissue Dysfunction in Nascent Metabolic Syndrome
Table 2
Novel adipokine concentrations.
| Variable | Controls () | MetS () | value MetS versus control |
| hsCRP (mg/L) | 1.3 (0.5, 4.0) | 3.1 (1.6, 5.4) | 0.006 | HOMA-IR | 1.1 (1.0, 2.8) | 2.8 (1.9, 5.1) | 0.0001 | Plasma chemerin (ng/mL) | 271 ± 53 | 366 ± 64 | <0.0001 | | |
*(0.0005) | SAT chemerin (ng/mg protein) | 3.05 ± 0.94 | 3.94 ± 0.74 |
0.001 | | | Plasma omentin (ng/mL) | 27 ± 14 | 16 ± 5 | 0.004 | | |
*(0.03) | SAT omentin (ng/mg protein) | 0.31 ± 0.09 | 0.22 ± 0.10 |
0.01 | | | Plasma resistin (ng/mL) | 1.8 (1.5, 2.5) | 2.4 (1.7, 3.1) | 0.04 | | |
*(0.07) | SAT resistin (ng/mg protein) | 0.16 ± 0.06 | 0.17 ± 0.05 |
NS | | | Plasma visfatin (ng/mL) | 0.57 (0.38, 0.71) | 0.59 (0.31, 0.96) | 0.14 | | |
*(0.13) | SAT visfatin (ng/mg protein) | 0.17 ± 0.09 | 0.21 ± 0.1 |
NS | | |
|
|
*( value adjusted for age and BMI). Results are presented as mean ± standard deviation or median (25th percentile and 75th percentile).
|